| The United States of America, As Represented By The Secretary, Department of Patent applications |
| Patent application number | Title | Published |
|---|
| 20110052631 | INDUCTION OF PROLIFERATION, EFFECTOR MOLECULE EXPRESSION, AND CYTOLYTIC CAPACITY OF HIV-SPECIFIC CD8+ T CELLS - Provided is a method of activating an immune cell of a subject with Human Immunodeficiency Virus (HIV), comprising contacting the immune cell with a phorbol ester and a calcium ionophore. Also provided is a composition comprising immune cells of a subject diagnosed with HIV, wherein the immune cells are activated by contact with a phorbol ester and a calcium ionophore. Methods of using the disclosed compositions are also disclosed. | 03-03-2011 |
| 20100314250 | STABILIZATION OF COMPLEXES FOR GEL MOBILITY SHIFT, CHROMATOGRAPHY, AND CAPILLARY ELECTROPHORESIS - The invention provides a method of separating a complex comprising a first agent bound to a second agent from unbound agents comprising (a) preparing a gel comprising a gel matrix and a neutral solute, (b) placing one or more samples comprising the complex and unbound agents on the gel, and (c) applying an electrophoresis voltage across the gel and separating the complex from the unbound agents. The invention also provides methods of separating a complex comprising a first agent bound to a second agent from unbound agents by chromatography and capillary electrophoresis. | 12-16-2010 |
| 20090232839 | MELANOMA ASSOCIATED PEPTIDE ANALOGUES AND VACCINES AGAINST MELANOMA - The present invention is concerned with cancer treatment and diagnosis, especially with melanoma associated peptide analogues with improved immunogenicity, epitopes thereof, vaccines against melanoma, tumor infiltrating T lymphocytes recognizing the antigen and diagnostics for the detection of melanoma and for the monitoring of vaccination. The peptides according to the invention can be exploited to elicit native epitope-reactive Cm. Usage of the peptides with improved immunogenicity may contribute to the development of CTL-epitope based vaccines in viral disease and cancer. | 09-17-2009 |
